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OBJECTIVES: Olanzapine and risperidone are the two most
widely used second-generation antipsychotic medications by Cal-
ifornia Medicaid (Medi-Cal) patients with severe mental disor-
ders. This analysis investigates the factors associated medication
choice by Medi-Cal patients with bipolar disorders who restart
therapy after a break in treatment. METHOD: Paid claims data
were analyzed to identify antipsychotic ‘re-starter’ treatment
episodes initiated between January 1999 and March 2003. An
episode was deﬁned each time a patient re-started therapy on a
new medication or restarted the same drug after a break of 15
days or more. Only re-starter episodes with olanzapine or risperi-
done were selected if 6 months of pre-treatment and 12 months
of post-treatment data were available. Multivariate logistic
regression was used to investigate the factors that affected treat-
ment choice. RESULTS: A total of 90,282 treatment episodes
meet study selection criteria. Olanzapine was the initial medica-
tion in 56% of re-starter episodes. Mean age was 39 and the
mean duration of uninterrupted treatment was 170 days.
Patients in every age category over 25 years of age were between
24% to 46% more likely to receive olanzapine, as were Asian
patients (+11%) and patients with prior use of psychiatric hos-
pital care (+6%). The likelihood of using olanzapine also
increased signiﬁcantly with the cost of non-institutional care con-
sumed in the prior 6 months. Risperidone patients were more
likely to be female (+10%), AFDC recipients (21%), urban
(+6%) or rural (6%) residents, Hispanic (+7%), black (+9%),
other minority (+7%) diabetic (+23%) and have a history of
prior nursing home use (+10%)(p < 0.05 for all results). CON-
CLUSION: Physicians in California used olanzapine and risperi-
done differentially to treat bipolar disorders. The observed
differences in patient characteristics for olanzapine and risperi-
done patients will affect both treatment outcomes and post-
treatment costs and must be adjusted for before comparing 
the outcomes achieved using these agents.
PMH16
OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF
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OBJECTIVES: In a direct comparison of patients with bipolar
manic or mixed episodes, olanzapine and risperidone showed
similar efﬁcacy in mania ratings (Baker, APA 2003), but olanza-
pine had greater efﬁcacy on clinician global impression of sever-
ity (CGI-S). We performed a post-hoc analysis investigating
possible determinants of this differential treatment effect.
METHODS: This 3-week, double-blind study compared olan-
zapine (5–20mg/day; N = 165) to risperidone (1–6mg/day; N =
164) in manic or mixed episodes. Path analysis dissected the
CGI-S treatment effect into drug effect explainable by effects on
manic, depressive and extrapyramidal symptoms, measured 
by standard rating scales, versus other treatment effects not
accounted for by rating scales. Demographic and disease char-
acteristics were examined to determine if they were signiﬁcant
predictors of CGI-S improvement. Analysis of variance and
regression models used change from baseline to endpoint (last
observation carried forward) for all analyses. RESULTS: Olan-
zapine-treated patients achieved signiﬁcantly greater improve-
ment in CGI-S than risperidone-treated patients (p = 0.014).
While changes in manic and depressive symptoms were signiﬁ-
cant predictors of the change in CGI-S (both p < 0.001), treat-
ment effect remained statistically signiﬁcant (p = 0.006) even
after adjustment for change in these effects. In fact, 93% of olan-
zapine’s superior treatment effect on CGI-S was not attributable
to changes in mania, depression, or extrapyramidal symptoms.
Race, gender, rapid cycling status, manic vs. mixed diagnosis, age
of disease onset, and weight change were not signiﬁcant deter-
minants of CGI-S change. A signiﬁcant interaction was detected
between age and treatment: older olanzapine-treated patients
had greater CGI improvement compared to older risperidone
patients; no differences occurred between treatments for younger
patients. CONCLUSIONS: Rating scale, demographic, and
illness characteristics were at most modest determinants of
improvement in global illness severity. Even after adjusting for
signiﬁcant determinants, olanzapine-treated patients still experi-
enced signiﬁcantly greater improvement than risperidone-treated
patients in global illness severity.
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OBJECTIVE: American Psychiatric Association (APA) practice
guidelines do not recommend antidepressant monotherapy in
patients with bipolar disorder, given the risk of precipitating a
switch into mania. However, few data have provided empirical
evidence to support such a guideline from the population per-
spective. This study assesses the clinical and economic impact 
of antidepressant monotherapy in patients with bipolar dis-
order. METHODS: Subjects with bipolar disorder were identi-
ﬁed among continuously enrolled adult members in a national
managed care plan between January 1997 and June 2002. A total
of 34,493 monotherapy episodes for 13,016 bipolar patients
were deﬁned based on the computerized diagnosis and pharmacy
records. Log-transformed multivariate models were employed to
identify the relationship between the type of monotherapy (mood
stabilizers, antidepressants, or antipsychotics) and 6-month
bipolar-related health care costs after the treatment discontinu-
ation. RESULTS: Antidepressant monotherapy use was highly
prevalent in this patient population, with rates ranging from
55% to 64% over the 5-year period. Controlling for age, gender,
regional differences, and disease severity, bipolar-related health
care costs signiﬁcantly increased with longer duration of antide-
pressant monotherapy (p < 0.0001). However no such relation-
ship was observed with mood stabilizer monotherapy (p = 0.36)
or antipsychotic monotherapy (p = 0.37). This increase in costs
with antidepressant monotherapy was due to an increased risk
of manic switching (1.3% per person-month) compared to mood
stabilizer use (p < 0.0001). CONCLUSIONS: This study pro-
vides evidence of adverse clinical and economic outcomes fol-
lowing antidepressant use in a bipolar population. In spite of the
known risk of manic switching with antidepressant monother-
apy, use remained high from 1997–2002. Systematic educational
efforts are needed to communicate treatment guidelines.
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OBJECTIVE: The California Medicaid program (Medi-Cal) 
initiated open access to atypical antipsychotic medications in
October 1997. This analysis evaluates the impact of open access
on drug therapy outcomes and treatment costs in patients with
bipolar disorder. METHODS: We conducted a retrospective
database analysis of patients diagnosed with bipolar disorder
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who initiated an episode of drug therapy between July 1994 and
December 31, 1999. Episodes were required to have a minimum
of 6 months of pre-treatment and 12 months of post-treatment
data. Episodes were then separated into three time periods: 
a “closed-access period” prior to October 1997, a “transition
period” covering the ﬁrst 6 months of open access, and an “open
access period” for episodes initiated after April 1, 1998. Multi-
variate regression models were used to estimate the impact of
open access on total health care costs and duration of therapy.
COX proportional hazard models were estimated for time to dis-
continuation. RESULTS: The number of patients re-starting drug
therapy or augmenting an existing therapy increased immedi-
ately with open access due to increased use of second-generation
medications. Episode initiation rates returned to pre-open access
levels within 6 months (transition period). Open access signiﬁ-
cantly reduced total costs primarily due to signiﬁcant savings in
nursing home care ($1700 and $1807 for re-starters and aug-
menters, respectively). However, drug persistence also declined
with open-access: 42 fewer days for re-starters and 33 fewer days
for augmenters. Augmenters and re-starters were 16% and 12%
more likely to discontinue therapy if their episodes were initiated
in the open access period. CONCLUSIONS: The decision to
include atypical antipsychotics by the Medi-Cal program
resulted in lower persistency of drug therapy and lower total
health care costs. Decision-makers and program administrators
must use caution in evaluating the impact of open access to new
antipsychotic medications on patient outcomes and costs.
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OBJECTIVES: Kleptomania involves stealing items that are not
needed or have limited value from shops, strangers and acquain-
tances. Its prevalence is estimated at 6 per 1000 U.S. adults.
Kleptomania appears to account for 5% of shoplifting. No con-
trolled trials of pharmacotherapy for kleptomania have been
published. We are conducting the ﬁrst controlled trial of a med-
ication for kleptomania. METHODS: We are enrolling adults
aged 20 and older with kleptomania of 1 year’s duration,
meeting DSM-IV criteria and marked by court referral or steal-
ing at least once per week. We exclude individuals with psychotic
disorders, alcohol or substance abuse, bipolar disorder or anti-
social personality disorder. Subjects receive open-label escitalo-
pram 10mg/day for 4 weeks and if not “much improved,” take
20mg/day for an additional 3 weeks. A “responder” is a patient
experiencing at least 50% decrease in the Y-BOCS-kleptomania
version (Y-BOCS-K) scale score and a CGI-I score of much or
very much improved. Responders are randomized double blind
to continue for four months on either escitalopram or placebo.
RESULTS: We have enrolled 13 patients of a planned 24. Eleven
completed the seven weeks of open-label escitalopram; two dis-
continued. The 11 completers include 9 women with a mean age
of 46 years. Nine are employed full-time, one unemployed and
one a student. Five are married, three single, three divorced. Ten
of the 11 received escitalopram 20mg/day. The completers’ mean
Y-BOCS-K score decreased from 23.1 (SD 5.1) to 8.6 (SD 7.8)
at end of week 7. On a 0–4 scale, the strength of urges to steal
decreased from a mean of 2.9 (SD 0.7) to 1.1 (SD 0.8). The mean
number of weekly urges to steal decreased from 3.0 (SD 0.6) to
1.6 (SD 1.1). Eight subjects were responders. Of these eight, four
relapsed during the 4-month double blind, placebo-controlled
phase, but the blind remains unbroken. CONCLUSIONS: Early
results suggest a therapeutic effect for escitalopram in treating
kleptomania.
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OBJECTIVE: To compare rehospitalization rates of individuals
with schizophrenia who had been treated and discharged on
olanzapine or quetiapine from acute care hospitals. METHODS:
Using Premier’s PerspectiveTM database—the largest U.S. hos-
pital drug utilization database, rehospitalization status was
examined for inpatients with schizophrenia (ICD9-CM: 295.xx)
that were successfully treated and discharged on olanzapine (N
= 7573) or quetiapine (N = 3368) between January 1999 and
September 2001. A successfully treated patient was one who
started treatment with olanzapine or quetiapine in hospital and
discharged on the same antipsychotic. Time to readmission up
to 33 months was analyzed by Kaplan-Meier models. Cox pro-
portional hazard models were used to derive the hazard ratio
(HR) for rehospitalization by adjusting potential confounding
factors. RESULTS: Overall rehospitalization rate in the study
population was 35.3%. After adjusting for potential confound-
ing factors, quetiapine therapy (average daily dose = 356.1mg)
was associated with 25% increased risk of rehospitalization
compared to olanzapine (average daily dose = 17.3mg) (HR =
1.25, 95% conﬁdence interval 1.17–1.34, p < 0.0001). Addi-
tionally, younger age, schizoaffective/paranoid diagnoses, higher
severity level, and urban hospital location were signiﬁcantly
associated with higher risk of readmission. CONCLUSIONS:
This study suggests that olanzapine-treated patients had lower
risk of rehospitalization than quetiapine-treated patients. More-
over, certain patient demographic/clinical factors and institution
characteristics also inﬂuenced hospital readmission.
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OBJECTIVE: Quetiapine’s relatively broad dosage guidelines
(150–750mg/day) may result in suboptimal dosing. This study
investigated the association between quetiapine dose levels and
efﬁcacy as reﬂected in mental health resource use by patients
with schizophrenia or bipolar disorder. METHODS: Patients
who initiated quetiapine monotherapy and were treated for at
least 4 months were identiﬁed in a large health plan database
(1999–2002). Use of mental health resources other than queti-
apine was measured by charges on all medical claims for mental
disorders (ICD-9-CM codes 290.xx–316.xx) and on all pre-
scription claims for other psychotropic medications. Each
patient’s ﬁrst quetiapine prescription was used to identify the
target daily dose, because subsequent adjustments may have rep-
resented an effect rather than a determinant of health resource
use, which was measured in months 2, 3, and 4 of treatment.
Regression models controlling for patient differences measured
associations between initial quetiapine dose and subsequent
mental health charges. A signiﬁcant negative association between
dose levels and mental health resource use may be an indicator
of suboptimal dosing. RESULTS: Patients with schizophrenia (N
